#United States #New York #Securities Fraud #Reckitt Benckiser #RBGLY

Investors Have an Opportunity to Lead in a Class Action

In a significant development for investors of Reckitt Benckiser Group PLC (OTC: RBGLY), the Rosen Law Firm, which specializes in investor rights, has issued a reminder for purchasers of American Depositary Shares (ADSs) during the specific period from January 13, 2021, to July 28, 2024. These individuals may find themselves at the forefront of a class-action lawsuit which has a crucial lead plaintiff deadline approaching on August 4, 2025.

What This Means for Investors

If you have purchased Reckitt's ADSs, there is a pathway available for you to potentially receive compensation without incurring out-of-pocket expenses, thanks to a contingency fee arrangement provided through Rosen Law Firm. This structure allows investors to pursue compensation without paying upfront fees or costs, which is often a barrier to seeking legal recourse.

Steps to Join the Class Action

To participate in the Reckitt class action lawsuit, interested parties are encouraged to visit Rosen Legal's submission page or can contact Phillip Kim, Esq., toll-free at 866-767-3653, or through email at [email protected] It's important to note that a class action lawsuit has already been initiated. However, anyone wishing to step into the role of lead plaintiff must file their motion with the Court by the given deadline. The lead plaintiff serves as a representative party for other class members during the litigation process.

The Necessity of Qualified Legal Counsel

The Rosen Law Firm emphasizes the importance of choosing qualified legal counsel with a proven record in leading similar lawsuits. Numerous firms may advertise their services but often lack the expertise, resources, or recognition in handling securities class actions. Some may act as intermediaries rather than actual litigators. The Rosen Law Firm prides itself on its global representation of investors, focusing solely on securities class actions and shareholder derivative litigation. Notably, the firm previously secured the largest-ever securities class action settlement against a Chinese company and has consistently ranked among the top legal firms in the field.

Case Details: The Allegations

According to the allegations in the lawsuit, during the class period, defendants—including Reckitt—failed to inform investors regarding critical health risks linked to Reckitt's cow's milk-based formula, Enfamil. The formula was allegedly associated with an increased risk of developing necrotizing enterocolitis (NEC) in preterm infants. Furthermore, the lawsuit claims Reckitt did not disclose the implications of these issues on the sales of Enfamil or the company's legal liabilities, resulting in misleading statements about the company's performance and future prospects.

When these critical facts were ultimately acknowledged in the market, investors experienced significant losses—and the class-action lawsuit aims to address these grievances.

Important Reminder for Investors

Investors should note that no class has been certified as of yet. Without certification, participants are not represented by legal counsel unless they actively retain one. Individuals may choose to remain members of the class without taking any immediate action, yet they should be aware that their ability to benefit from potential recoveries in the future does not hinge on becoming the lead plaintiff.

Staying Updated

For ongoing updates regarding the lawsuit, stakeholders are encouraged to follow the Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook. These channels will provide all necessary information for interested parties as the lawsuit progresses.

In conclusion, if you are among the purchasers of Reckitt ADSs during the specified period, consider your options seriously. The opportunity to lead in this class action may not only provide a path toward potential financial redress but also foster a sense of communal action among those affected by this significant issue.